Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…

John Northcott Biography and Net Worth

SVP of Nektar Therapeutics

John Northcott joined Nektar in December 2019 as Senior Vice President and Chief Commercial Officer to lead commercial strategy, marketing, sales, analytics, commercial operations, and market access functions for the company. Mr. Northcott brings extensive commercial experience to Nektar, including both pre-launch planning and commercialization in oncology and other therapeutic areas. Most recently, John served as the Chief Commercial Officer of Pharmacyclics from 2015 to 2019, where he led all commercial functions for Imbruvica^® (ibrutinib).

From 2013 to 2015, Mr. Northcott was Chief Commercial Officer at Lexicon Pharmaceuticals where he led commercial strategy and operations for all products and therapeutic areas. From 2007 to 2013, he held commercial roles in both U.S. and Global marketing for Avastin^® (bevacizumab) with Genentech and the Roche Group, having most recently served as International Business Leader for Avastin, leading global product strategy initiatives in oncology. Prior to his time at Roche/Genentech, Mr. Northcott held management positions in sales and marketing in a variety of therapeutic areas at other pharmaceutical companies including Merck and Pfizer.

Mr. Northcott holds a B.A. degree in Business Administration from St. Francis Xavier University.

How do I contact John Northcott?: The corporate mailing address for Mr. Northcott and other Nektar Therapeutics executives is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. Nektar Therapeutics can also be reached via phone at (415) 482-5300 and via email at [email protected]. Learn More on John Northcott's contact information.
Has John Northcott been buying or selling shares of Nektar Therapeutics?: John Northcott has not been actively trading shares of Nektar Therapeutics within the last three months. Most recently, John Northcott sold 4,852 shares of the business's stock in a transaction on Wednesday, February 16th. The shares were sold at an average price of $10.95, for a transaction totalling $53,129.40. Learn More on John Northcott's trading history.
Who are Nektar Therapeutics' active insiders?: Nektar Therapeutics' insider roster includes Robert Chess (Director), Myriam Curet (Director), Gil Labrucherie (CFO), John Northcott (SVP), Howard Robin (CEO), Jillian Thomsen (CAO), Mark Wilson (SVP), and Jonathan Zalevsky (Insider). Learn More on Nektar Therapeutics' active insiders.
Are insiders buying or selling shares of Nektar Therapeutics?: During the last year, insiders at the biopharmaceutical company sold shares 10 times. They sold a total of 174,362 shares worth more than $236,980.50. The most recent insider tranaction occured on November, 19th when insider Jonathan Zalevsky sold 7,785 shares worth more than $7,862.85. Insiders at Nektar Therapeutics own 3.7% of the company. Learn More about insider trades at Nektar Therapeutics.
Information on this page was last updated on 11/19/2024.

John Northcott Insider Trading History at Nektar Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/16/2022	Sell	4,852	$10.95	$53,129.40

John Northcott Buying and Selling Activity at Nektar Therapeutics

Nektar Therapeutics Company Overview

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Today's Range

Now: $1.00

$1.00

$1.07

50 Day Range

MA: $1.28

$1.00

$1.45

2 Week Range

Now: $1.00

$0.42

$1.93

Volume

1,485,696 shs

Average Volume

1,798,017 shs

Market Capitalization

$184.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.61